Abstract 466P
Background
Brain stem tumors are among the most severe oncological diseases in children. The only real method of help remains radiation therapy, which makes it possible to alleviate the severity of neurological disorders, but for most patients, the effect achieved, regardless of the type of ionizing radiation used, is temporary and after various periods (from 3 months to several years), the tumor resumes growth. The main purpose of our work was to determine the possibilities and prospects of repeated radiation therapy in children with diffuse brain stem tumors.
Methods
In the period 1998-2022, analysis of short and long-term results of 132 children and adolescents with brainstem tumors treated at the Russian Scientific Center of Roentgenoradiology were evaluated. Out of 132 patients treated at RNCRR, 60 children were selected whose remission lasted more than 9 months and the Lansky scale of more than 40 points for re-irradiation.
Results
As a result of re-irradiation, out of 45 children with a Lansky status of 40-50 points, it was improved in 36 (80%). An additional 15 children were included in the group with an initial Lansky status of 70-90 points, initially represented by one child, and only 9 patients' condition worsened or did not change. The median life expectancy in the group of patients after one course of radiation therapy was 13.9 months, but in the group of those treated repeatedly - 22.6 months.
Conclusions
Re-irradiation using 30.0 to 45.0 Gy in standard fractionation in combination with adequate accompanying therapy in 90% of cases allows an increase in the remission period in dense tumors and temporarily improve the quality of life in cystic solid tumors.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
556P - Predicting the efficacy of neoadjuvant chemoradiotherapy in rectal cancer patients based on dynamic tumor-informed ctDNA-MRD
Presenter: Weiwei Xiao
Session: Poster session 16
557P - Three-year update of real-world evaluation of ColonAiQ for colorectal cancer screening in asymptomatic individuals
Presenter: Baohua Wang
Session: Poster session 16
558P - Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: Subgroup analysis from CIRCULATE-Japan GALAXY
Presenter: Kozo Kataoka
Session: Poster session 16
561P - Liquid biopsy tracking of immunotherapy-induced T cell dynamics in MSS colorectal and endometrial tumors
Presenter: Holger Heyn
Session: Poster session 16
562P - Acquired genomic alterations on first-line chemotherapy (CT) + cetuximab in advanced colorectal cancer (mCRC): Circulating tumor (ct)DNA analysis of the randomized phase II trial TIME-PRODIGE-28
Presenter: Valerie Boige
Session: Poster session 16
564P - Short-course radiotherapy combined with chemotherapy and PD-1 inhibitor in proficient mismatch repair or microsatellite stable (pMMR/MSS) low-lying early rectal cancer: Preliminary findings from a prospective, multi-center, phase II trial (TORCH-E)
Presenter: Fan Xia
Session: Poster session 16
565P - Neoadjuvant chemotherapy, excision, and observation for early rectal cancer: The phase II NEO trial (CCTG CO.28) results after minimum 3 years follow up
Presenter: Carl Brown
Session: Poster session 16